Year All2024202320222021 KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial 03-21-2022 KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system) 03-16-2022 KemPharm to Report Fourth Quarter and Full-Year 2021 Results 03-10-2022 KemPharm Completes KP1077 Pre-IND Meeting Process with FDA 02-23-2022 KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy 01-19-2022 KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion 01-12-2022 KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference 01-11-2022 KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022” 01-06-2022 KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program 12-20-2021 KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX” 12-14-2021
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial 03-21-2022
KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system) 03-16-2022
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy 01-19-2022
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference 01-11-2022
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX” 12-14-2021